IBSA Institut Biochimique v. Accord Healthcare: Levothyroxine Patent Dispute Settled
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | IBSA Institut Biochimique S.A. v. Accord Healthcare, Ltd. |
| Case Number | 2:23-cv-00054 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Jan 2023 – Sep 2025 978 days |
| Outcome | Settled |
| Patents at Issue | |
| Accused Products | Accord Healthcare’s Levothyroxine Sodium Oral Solution |
Case Overview
The Parties
⚖️ Plaintiff
Swiss biopharmaceutical company with expertise in thyroid, gynecology, and pain management therapeutics, joined by U.S. affiliate IBSA Pharma, Inc. and co-plaintiff Altergon SA.
🛡️ Defendant
A subsidiary of Intas Pharmaceuticals and a prominent global generic drug manufacturer, sought to enter the U.S. market with its own levothyroxine sodium oral solution product.
Patents at Issue
This landmark case involved three U.S. patents asserted, all directed to levothyroxine sodium oral solution formulations and methods:
- • US 11,241,382 B2 — Levothyroxine sodium oral solution formulations and methods.
- • US 10,537,538 B2 — Levothyroxine sodium oral solution formulations and methods.
- • US 11,096,913 B2 — Levothyroxine sodium oral solution formulations and methods.
These patents collectively protect proprietary formulation technology underlying liquid thyroid hormone therapy—a dosage form particularly critical for pediatric patients and individuals unable to swallow tablets.
Developing a similar drug formulation?
Check if your product might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The District of New Jersey reported to the Court that the action had been settled by the parties, resulting in case closure on September 9, 2025. This is a consensual resolution—no judicial finding of infringement, validity, or invalidity was entered. Specific settlement terms, including any licensing arrangements, milestone payments, or authorized generic entry dates, were not publicly disclosed, which is standard practice in pharmaceutical patent settlements.
Key Legal Issues
The case was brought as a patent infringement action—the operative legal trigger most commonly arising in the pharmaceutical context through the Hatch-Waxman Act framework. With three overlapping patents asserted, plaintiffs constructed a layered exclusivity defense, increasing the burden on generic challengers. Accord Healthcare’s decision to settle rather than litigate to judgment suggests that the cumulative strength of the patent portfolio, the uncertainty of claim construction outcomes, or commercial considerations made resolution preferable to trial risk.
Filing a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis in Pharma
This case highlights critical IP risks in pharmaceutical formulations. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View related patents in levothyroxine space
- See key players in thyroid therapeutics
- Understand formulation claim patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your formulation or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Levothyroxine oral solution formulations
3 Asserted Patents
Covering formulation and methods
Complex IP Landscape
Requires thorough FTO analysis
✅ Key Takeaways
For Patent Attorneys
Multi-patent assertion strategies in pharmaceutical cases create compounding risk for generic challengers and frequently drive settlement before trial.
Search related case law →Hatch-Waxman litigation in the District of New Jersey continues to settle at high rates, often before claim construction.
Explore precedents →For R&D Teams
Liquid formulation product development in established drug categories requires comprehensive patent landscape analysis across entire patent families.
Start FTO analysis for my product →Three-patent assertion portfolios signal robust prosecution investment—budget FTO analysis accordingly.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.